Physician profile
Mark Phillip Baker
NPI 1821450834
$833.96
in general payments reported to CMS, 2019-2025
11 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $159 · 2021: $135 · 2022: $104 · 2023: $80.02 · 2024: $124 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $191.67 | 2019-2020 | |
| Abbvie INC. | $169.75 | 2023-2025 | |
| Daiichi Sankyo INC. | $118.04 | 2021 | |
| Lilly USA, LLC | $92.67 | 2020 | |
| Amgen INC. | $86.85 | 2022 | |
| Abbott Laboratories | $48.74 | 2024 | Freestyle Libre 3 |
| Procept Biorobotics Corporation | $34.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $34.59 | 2023 | Farxiga |
| Novo Nordisk INC | $22.93 | 2023 | Wegovy |
| Eisai INC. | $16.99 | 2021 | |
| Janssen Biotech, INC. | $16.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.